Veysel SÜZERER, İsmail YENER, Abdulselam ERTAŞ, Mustafa Abdullah YILMAZ, Remzi EKİNCİ, Emine AYAZ TİLKAT, Sevgi İRTEGÜN KANDEMİR, Ahmet ONAY, Nesrin BOZHAN

Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?

To combat the coronaviruses and their novel variants, therapeutic drugs and the development of vaccines that are to be effective throughout human life are urgently needed. The endocannabinoid system (ECS) acts as a modulator in the activation of the microcirculation, immune system, and autonomic nervous system, along with controlling pharmacological functions such as emotional responses, homeostasis, motor functions, cognition, and motivation. The ECS contains endogenous cannabinoids, cannabinoid receptor (CBRs), and enzymes that regulate their biosynthesis, transport, and degradation. Moreover, phytocannabinoids and synthetic cannabinoids that mimic the action of endocannabinoids also play an essential role in the modulation of the ECS. Cannabinoids, the main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received international attention in the health field due to their therapeutic properties. Recently, they have been tested for the treatment of COVID-19 due to their antiviral properties. Indeed, cannabinoid-type compounds, and in particular cannabidiol (CBD), isolated from glandular trichomes found in the calyx of cannabis flowers with reported antiviral properties is hypothesized to be a therapeutic option in the ministration of SARS-CoV-2 consorted with COVID-19 disease. The relevant articles were determined from the database search published mainly in Web of Science, Google scholar, PubMed, Crossref, and ClinicalTrials.gov database during the pandemic period. The articles were evaluated for the therapeutic potentials, mechanisms of action of cannabinoids, the roles of the ECS in the immune system, impact of cannabinoids in SARS-CoV-2 septic, especially if they address the application of cannabinoids as drugs for the curability and management of SARSCoV-2 and its novel variants. Although the evidence needed to be considered using cannabinoids in the control and treatment of viral diseases is currently in its infancy, they already offer an opportunity for clinicians due to their effects in relieving pain, improving appetite, and improving childhood epilepsy, especially in cancer and human immunodeficiency virus (HIV/AIDS) patients. In addition to these, the most recent scientific evidence emphasizes their use in the treatment of the coronavirus infected patients. In brief, all preclinic and clinic studies that have been reported show that, through the cannabinoid system, cannabinoids, particularly CBD, have many mechanisms that are effective in the treatment of patients infected by SARS-CoV-2. Thus, more extensive studies are necessary in this area to fully identify the effects of cannabinoids on SARS-CoV-2.

PDF

___

Abdallah SJ, Smith BM, Ware MA, Moore M, Li PZ et al. (2018). Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial. Annals of the American Thoracic Society 15 (10): 1146-1158. doi: 10.1513/AnnalsATS.201803-198OC
Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S et al. (2020). Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. International Journal of Biological Macromolecules 164: 1693-1703. doi: 10.1016/j. ijbiomac.2020.07.235
Alhouayek M, Muccioli GG (2014). COX-2- derived endocannabinoid metabolites as novel inflammatorymediators. Trends in Pharmacological Sciences 35 (6): 284-92. doi: 10.1016/j.tips.2014.03.001
Al-Khafaji K, Al-Duhaidahawi D, Taskin TT (2020). Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. Journal of Biomolecular Structure and Dynamics 39 (9): 3387-3395. doi: 10.1080/07391102.2020.1764392
Almada M, Alves P, Fonseca BM, Carvalho F, Queiros CR et al. (2020). Synthetic cannabinoids JWH-018, JWH-122, UR144 and the phytocannabinoid THC activate apoptosis in placental cells. Toxicology Letters 319: 129-137. doi: 10.1016/j.toxlet.2019.11.004
Almogi-Hazan O, Or R (2020). Cannabis, the endocannabinoid system and immunity-the journey from the bedside to the bench and back. International Journal of Molecular Sciences 21 (12): 4448. doi: 10.3390/ijms21124448
Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D et al. (2021). Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Scientific Reports 11: 1462. doi: 10.1038/ s41598-021-81049-2
Apostu D, Lucaciu O, Mester A, Benea H, Oltean-Dan D et al. (2019). Cannabinoids and bone regeneration. Drug Metabolism Reviews 51 (1): 65-75. doi: 10.1080/03602532.2019.1574303
Badowski ME, Yanful PK (2018). Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Therapeutics and Clinical Risk Management 14: 643-651. doi: 10.2147/TCRM.S126849
Baggelaar MP, Maccarrone M, Van der Stelt M (2018). 2-Arachidonoylglycerol: a signaling lipid with manifold actions in the brain. Progress in Lipid Research 71: 1-17. doi: 10.1016/j.plipres.2018.05.002
Bian J, Li Z (2021). Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharmaceutica Sinica B 11 (1): 1-12. doi: 10.1016/j. apsb.2020.10.006
Boechat JL, Chora I, Morais A, Delgado L (2021). The immune response to SARS-CoV-2 and COVID-19 immunopathology–current perspectives (in press). Pulmonology doi: 10.1016/j.pulmoe.2021.03.008
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M et al. (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235 (7): 1923-1932. doi: 10.1007/s00213-018-4885-9
Burki T (2021). Understanding variants of SARS-CoV-2. The Lancet 397 (10273): 462. doi: 10.1016/S0140- 6736(21)00298-1
Burstein S (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic and Medicinal Chemistry 23 (7): 1377-1385. doi: 10.1016/j. bmc.2015.01.059
Byrareddy SN, Mohan M (2020). SARS-CoV-2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Brain, Behavior, and Immunity 87: 120-121. doi: 10.1016/j.bbi.2020.04.079
Cabral GA, Griffin-Thomas L (2009). Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine 11: e3. doi: 10.1017/ S1462399409000957
Capano A, Weaver R, Burkman E (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine 132 (1): 56-61. doi:10.1080/0 0325481.2019.1685298
Chatow L, Nudel A, Nesher I, Hayo-Hemo D, Rozenberg P et al. (2021). In vitro evaluation of the activity of terpenes and cannabidiol against human coronavirus E229. Life 11 (4): 290. doi: 10.3390/life11040290
Cinat J, Morgenstern B, Bauer G, Chandra P, Rabenau H et al. (2003). Glycyrrhizin, an active component of liquorice roots and replication of SARS-associated coronavirus. The Lancet 361: 2045–2046. doi: 10.1016/S0140-6736(03)13615-X
Cohen K, Weinstein A (2018). The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids-a systematic review. Brain Sciences 8 (3): 40. doi: 10.3390/brainsci8030040
Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R et al. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents 34 (2): 1. doi: 10.23812/CONTI-E
Costiniuk CT, Jenabian MA (2020). Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?. Cytokine and Growth Factor Reviews 53: 63-65. doi: 10.1016/j. cytogfr.2020.05.008
Costiniuk CT, Saneei Z, Routy J, Margolese S, Mandarino E et al. (2019). Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028- study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open 9 (1): e024793. doi: 10.1136/bmjopen-2018-024793
Couch DG, Cook H, Ortori C, Barrett D, Lund JN et al. (2019). Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo—a randomized, placebo-controlled, double-blind controlled trial. Inflammatory Bowel Diseases 25 (6): 1006-1018. doi: 10.1093/ibd/izz017
Desai AN, Patel P (2020). Stopping the spread of COVID-19. The Journal of the American Medical Association 323 (15): 1516-1516. doi: 10.1001/jama.2020.4269
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (5090): 1946-1949. doi: 10.1126/science.1470919
Dujourdy L, Besacier F (2017). A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Science International 272: 72-80. doi: 10.1016/j. forsciint.2017.01.007
Ebbert JO, Scharf EL, Hurt RT (2018). Medical cannabis. Mayo Clinic Proceedings 93 (12): 1842-1847. doi: 10.1016/j. mayocp.2018.09.005
Egmond NV, Straub VM, Der Stelt MV (2021). Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annual Review of Pharmacology and Toxicology 61: 441-463. doi: 10.1146/annurevpharmtox-030220-112741
Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW (2007). Anandamide and Δ9 -tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. Journal of Neuroimmunology 189 (1-2): 17-22. doi: 10.1016/j.jneuroim.2007.06.001
El Biali M, Broers B, Besson M, Demeules J (2020). Cannabinoids and COVID-19. Medical Cannabis and Cannabinoids 3 (2): 111-115. doi: 10.1159/000510799
El-Sayed A, Kamel M (2021). Coronaviruses in humans and animals: the role of bats in viral evolution. Environmental Science and Pollution Research 28: 19589-19600 doi: 10.1007/s11356-021-12553-1
Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J et al. (2020). The potential of cannabidiol in the COVID‐19 pandemic. British Journal of Pharmacology 177 (21): 4967-4970. doi: 10.1111/bph.15157
Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS et al. (2000). Cannabinoid CB1 receptor expression in rat spinal cord. Molecular and Cellular Neuroscience 15: 510-521. doi: 10.1006/mcne.2000.0844
Feliu A, Moreno‐Martet M, Mecha M, Carrillo‐Salinas FJ, De Lago E et al. (2015). A Sativex® ‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology 172: 3579-3595. doi: 10.1111/bph.13159
Gadanec LK, McSweeney KR, Qaradakhi T, Ali B, Zulli A et al. (2021). Can SARS-CoV-2 virus use multiple receptors to enter host cells?. International Journal of Molecular Sciences 22 (3): 992. doi: 10.3390/ijms22030992
Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86 (8): 1646-1647. doi: 10.1021/ja01062a046
Ghaffari S, Roshanravan N, Tutunchi H, Ostadrahimi A, Pouraghaei M et al. (2020). Oleoylethanolamide, a bioactive lipid amide, as a promising treatment strategy for coronavirus/COVID-19. Archives of Medical Research 51 (5): 464-467. doi: 10.1016/j.arcmed.2020.04.006
Greenberg DA (2003). Endocannabinoids. In: Aminoff MJ, Daroff RB (editors). Encyclopedia of the Neurological Sciences. New York, NY, USA: Academic Press, pp. 143-144
Han Y, Kral P (2020). Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14 (4): 5143- 5147. doi: 0.1021/acsnano.0c02857
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z et al. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences 98 (7): 3662-3665. doi: 10.1073/ pnas.061029898
Hernandez-Cervantes R, Mendez-Diaz M, Prospero-Garcia O, Morales-Montor J (2017). Immunoregulatory role of cannabinoids during infectious disease. Neuroimmunomodulation 24 (4-5): 183-199. doi: 10.1159/000481824
Hill KP (2020). Cannabinoids and the coronavirus. Cannabis and Cannabinoid Research 5 (2): 118–120. doi: 10.1089/ can.2020.0035
Howlett AC, Abood MC (2017). $CB_1 & CB_2$ Receptor Pharmacology. Advances in Pharmacology 80: 169–206. doi: 10.1016/bs.apha.2017.03.007
Hu TY, Frieman M, Wolfram J (2020). Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature Nanotechnology 15 (4): 247-249. doi: 10.1038/s41565-020- 0674-9
Huang C, Wang Y, Li X, Ren L., Zhao J et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5
Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences 99 (12): 8400-8405. doi: 10.1073/pnas.122196999
Hui DS, Lee N, Chan PK, Beigel JH (2018). The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Research 150: 202-216. doi: 10.1016/j. antiviral.2018.01.002
Li HL (1974). An archaeological and historical account of cannabis in China. Economic Botany, 28 (4), 437-448. Published by: Springer on behalf of New York Botanical Garden Press
Iannotti FA, Vitale RM (2021). The endocannabinoid system and PPARs: Focus on their signalling crosstalk, action and transcriptional regulation. Cells 10 (3): 586. doi: 10.3390/ cells10030586
Karmous PWF, Gagner JG, Harkema JK, Kaminski NE, Kaplan BLF (2013). Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. Journal of Immunotoxiclogy 10 (3): 321-328. doi: 10.3109/1547691X.2012.741628
Kapellos TS, Taylor L, Feuerborn A, Valaris S, Hussain MT, Rainger GE, Greaves DR, Iqbal AJ (2019). Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment. The FASEB Journal 33: 6154-6167. doi.org/10.1096/fj.201802524R
Khodadadi H, Salles EL, Jarrahi A, Chibane F, Costigliola V et al. (2020). Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis and Cannabinoid Research 5 (3): 197-201. doi: 10.1089/can.2020.0043
Khuja I, Yekhtin Z, Or R, Almogi-Hazan O (2018). Cannabinoids reduce inflammation but inhibit lymphocyte recovery in murine models of bone marrow transplantation. International Journal of Molecular Sciences 20 (3): 668. doi:10.3390/ijms20030668
Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Ilnytskyy S et al. (2021). Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?. Aging (Albany NY) 13 (2): 1571–1590. doi: 10.18632/aging.202500
Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE et al. (2002). 15-Lipoxygenase metabolism of 2-arachidonylglycerol: Generation of a peroxisome proliferator-activated receptor α agonist. Journal of Biological Chemistry, 277 (26): 23278- 23286. doi: 10.1074/jbc.M201084200
Kozak KR, Rowlinson SW, Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. Journal of Biological Chemistry 275 (43): 33744–49. doi: 10.1074/jbc. M007088200
Kumar A, Premoli M, Aria F, Bonini SA, Maccarinelli G et al. (2019). Cannabimimetic plants: are they new cannabinoidergic modulators?. Planta 249 (6): 1681-1694. doi: 10.1007/s00425-019-03138-x
Laezza C, Pagano C, Navarra G, Pastorino O, Proto MC et al. (2020). The endocannabinoid system: A target for cancer treatment. International Journal of Molecular Sciences 21 (3): 747. doi: 10.3390/ijms21030747
Lauritsen KJ, Rosenberg H (2016). Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana. The American Journal of Drug and Alcohol Abuse 42 (4): 377-384. doi: 10.3109/00952990.2015.1135158
Li X, Hua T, Vemuri K, Ho JH, Wu Y et al. (2019). Crystal structure of the human cannabinoid receptor CB2. Cell 176 (3): 459-467. doi: 10.1016/j.cell.2018.12.011
Li HL (1974). The origin and use of Cannabis in Eastern Asia linguistic-cultural implications. Economic Botany 28 (3): 293-301. doi: 10.1007/BF02861426
Lima EMG, Tardelli VS, Brietzke E, Fidalgo TM (2021). Cannabis and inflammatory mediators. European Addiction Research 27 (1): 16-24. doi: 10.1159/000508840
Liu DX, Liang JQ, Fung TS (2021). Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encyclopedia of Virology (Fourth Edition) 2: 428-440. doi: 10.1016/ B978-0-12-809633-8.21501-X
Lowe R, Wu Y, Tamar A, Harb J, Abbeel P, Mordatch I (2017). Multi agent actor critic for mixed cooperative competitive environments. 31st Conference on Neural Information Processing Systems (NIPS 2017) 6382–6393 Long Beach, CA, USA.
Lu HC, Mackie K (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry 79 (7): 516-525. doi: 10.1016/j.biopsych.2015.07.028
Lucaciu O, Aghiorghiesei O, Petrescu NB, Mirica IC, Benea HRC et al. (2021). In quest of a new therapeutic approach in COVID-19: the endocannabinoid system. Drug Metabolism Reviews (in press). doi: 10.1080/03602532.2021.1895204
Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X et al. (2012). Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma–associated herpesvirus-infected endothelium. Genes and Cancer 3 (7-8): 512-520. doi: 10.1177/1947601912466556
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nature Medicine 13 (4): 492-497. doi: 10.1038/nm1561
Martinez V, Iriondo De-Hond A, Borrelli F, Capasso R, Del Castillo MD et al. (2020). Cannabidiol and other nonpsychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: Useful nutraceuticals?. International Journal of Molecular Sciences 21 (9): 3067. doi: 10.3390/ijms21093067
Mastinu A, Premoli M, Ferrari-Toninelli G, Tambaro S, Maccarinelli G et al. (2018). Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Hormone Molecular Biology and Clinical Investigation, 20180013. doi: 10.1515/hmbci -2018-0013
Mecha M, Feliu A, Inigo PM, Mestre L, Carrillo-Salinas FJ, et al. (2013). Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiology of Disease 59: 141-150. doi: 10.1016/j. nbd.2013.06.016
Mechoulam R, Peters M, Murillo‐Rodriguez E, Hanus LO (2007). Cannabidiol-recent advances. Chemistry and Biodiversity 4 (8): 1678-1692. doi: 10.1002/cbdv.200790147
Mills B, Yepes A, Nugent K (2015). Synthetic cannabinoids. The American Journal of the Medical Sciences 350 (1): 59-62. doi: 10.1097/MAJ.0000000000000466
Mohammed A, Alghetaa HK, Zhou J, Chatterjee S, Nagarkatti P et al. (2020). Protective effects of Δ9‐tetrahydrocannabinol against enterotoxin‐induced acute respiratory distress syndrome are mediated by modulation of microbiota. British Journal of Pharmacology 177 (22): 5078-5095. doi: 10.1111/bph.15226
Molaei S, Dadkhah M, Asghariazar V, Karami C, Safarzadeh E (2020). The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARSCoV-2: Vaccine design strategies. International Immunopharmacology 92: 107051. doi: 10.1016/j. intimp.2020.107051
Moran MM, McAlexander MA, Biro T, Szallasi A (2011). Transient receptor potential channels as therapeutic targets. Nature Reviews Drug Discovery 10: 601-620. doi: 10.1038/ nrd3456
Morrison AR, Johnson JP, Griebe KM, Stine JJ, Hencken LN, To L, Bianchini ML et al. (2020). Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Journal of Autoimmunity 114: 102512. doi: 10.1016/j.jaut.2020.102512
Nachnani R, Raup-Konsavage WM, Vrana KE (2021). The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics 376 (2): 204-212. doi: 10.1124/jpet.120.000340
Nagarkatti P, Miranda K, Nagarkatti M (2020). Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019. Frontiers in Pharmacology 11: 589438. doi: 10.3389/fphar.2020.589438
Nguyen LC, Yang D, Nicolaescu V, Best T, Chen S et al. (2021). Cannabidiol inhibits SARS-CoV-2 replication and promotes the host innate immune response. The Preprint Server for Biology (bioRxiv) (In Press). doi: 10.1101/2021.03.10.432967
Nichols JM, Kaplan BLF (2020). Immune responses regulated by cannabidiol. Cannabis and Cannabinoid Research 5: 12–31. doi:10.1089/can.2018.0073
Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science, 334 (6057): 809-813. doi:10.1126/science.1209200
Olah A, Szekanecz Z, Biro T (2017). Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges. Frontiers in Immunology 8:1487. doi.org/10.3389/fimmu.2017.01487
Onaivi ES, Sharma V (2020). Cannabis for COVID-19: can cannabinoids quell the cytokine storm?. Future Science OA 6 (8): FSO625. doi:10.2144/fsoa-2020-0124
Orio LP, Boschin G, Recca T, Morelli CF, Ragona L et al. (2017). New ACE-inhibitory peptides from hemp seed (Cannabis sativa L.) proteins. Journal of Agricultural and Food Chemistry 65 (48): 10482–10488. doi: 10.1021/acs. jafc.7b04522
Paland N, Pechkovsky A, Aswad M, Hamza H, Popov T et al. (2021). The immunopathology of COVID-19 and the Cannabis Paradigm. Frontiers in Immunology 12: 327. doi: 10.3389/fimmu.2021.631233
Paloczi J, Matyas C, Cinar R, Varga ZV, Hasko G et al. (2019). Alcohol binge-induced cardiovascular dysfunction involves endocannabinoid–CB1-R signaling. Basic to Translational Science 4 (5): 625-637. doi: org/j.jacbts.2019.05.007
Parks JM, Smith JC (2020). How to discover antiviral drugs quickly. New England Journal of Medicine 382 (23): 2261- 2264. doi: 10.1056/NEJMcibr2007042
Pereira JP, An J, Xu Y, Huang Y, Cyster JG (2009). Cannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids. Nature Immunology 10 (4):403- 411. doi: 10.1038/ni.1710
Pertwee RG (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current Medicinal Chemistry 17 (14): 1360-1381. doi: 10.2174/092986710790980050
Pertwee RG, Howlett, AC, Abood ME, Alexander SPH, Di Marzo V et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacological Reviews 62 (4): 588-631. doi: 10.1124/pr.110.003004
Petrescu NB, Jurj A, Soritau O, Lucaciu OP, Dirzu N, Raduly L et al. (2020). Cannabidiol and Vitamin D3 Impact on Osteogenic Differentiation of Human Dental Mesenchymal Stem Cells. Medicana (Kaunas) 56 (11): 607. doi: 10.3390/ medicina56110607
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G et al. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology and Therapeutics 175: 133- 150. doi: 10.1016/j.pharmthera.2017.02.041.
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics 301 (3): 1020-1024. doi: 10.1124/jpet.301.3.1020
Raj V, Park JG, Cho KH, Choi P, Kim T et al. (2021). Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. International Journal of Biological Macromolecules 168: 474-485. doi: 10.1016/j.ijbiomac.2020.12.020
Reiss CS (2010). Cannabinoids and viral infections. Pharmaceuticals 3 (6): 1873-1886. doi: 10.3390/ph3061873
Rohbeck E, Eckel J, Romacho T (2021). Cannabinoid receptors in metabolic regulation and diabetes. Physiology 36 (2): 102- 113. doi: 10.1152/physiol.00029.2020
Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R (2020). A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9 (5): 1267. doi: 10.3390/cells9051267
Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F (2020). Cannabinoid receptor type 2: A possible target in SARS-CoV-2 (CoV-19) infection?. International Journal of Molecular Sciences 21 (11): 3809. doi: 10.3390/ ijms21113809
Salles EL, Khodadadi H, Jarrahi A, Ahluwalia M, Paffaro Jr VA et al. (2020). Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. Journal of Cellular and Molecular Medicine 24 (21): 12869-12872. doi: 10.1111/ jcmm.15883
Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV (2021). Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. Journal of Psychopharmacology doi: 10.1177/0269881120986393
Shamran H, Singh NP, Zumbrun EE, Murphy A, Taub DD, Mishra MK et al. (2017). Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain, Behavior, and Immunity 59: 10–20. doi: 10.1016/j. bbi.2016.06.008
Shannon S, Lewis N, Lee H, Hughes S (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal 23: 18-41. doi: 10.7812/TPP/18-041
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research 24: 91-98. doi: 10.1016/j.jare.2020.03.005
Sledzinski P, Nowak-Terpiłowska A, Zeyland J (2021). Cannabinoids in medicine: Cancer, immunity, and microbial diseases. International Journal of Molecular Sciences 22: 263. doi: 10.3390/ijms22010263
Small E (1979). The species problem in Cannabis: science and semantics-v. 1: Science.-v. 2: Semantics.
Snider NT, Walker VJ, Hollenberg PF (2010). Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacological Reviews 62 (1): 136-154. doi: 10.1124/pr.109.001081
Soliman N, Haroutounian H, Hohmann A, Krane E, Liao J et al. (2021). A systematic review and meta-analysis of cannabisbased medicines, cannabinoids and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain (In Press). doi: 10.1097/j.pain.0000000000002269
Song Y, Zhang M, Yin L, Wang K, Zhou Y et al. (2020). COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARSCoV-2). International Journal of Antimicrobial Agents 56 (2): 106080 doi: 10.1016/j.ijantimicag.2020.106080
Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (6644): 773-778. doi: 10.1038/42015
Storozhuk MV, Zholos AV (2018). TRP channels as novel targets for endogenous ligands: focus on endocannabinoids and nociceptive signalling. Current Neuropharmacology 16 (2): 137-150. doi: 10.2174/1570159X15666170424120802
Tahamtan A, Tavakoli-Yaraki M, Rygel TP, Mokhtari-Azad T, Salimi V (2016). Effects of cannabinoids and their receptors on viral infections. Journal of Medical Virology 88 (1): 1-12. doi.org/10.1002/jmv.24292
Tay MZ, Poh CM, Renia L, Macary PA, Ng LFP (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology 20: 363-374. doi.org/10.1038/ s41577-020-0311-8
Turcotte C, Blanchet MR, Laviotte M, Flamand N (2016). Impact of Cannabis, Cannabinoids, and Endocannabinoids in the Lungs. Frontiers in Pharmacology 7: 317. doi: 10.3389/ fphar.2016.00317
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J et al. (2020). Immunology of COVID-19: current state of the science. Immunity 52 (6): 910-941. doi: 10.1016/j. immuni.2020.05.002
Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW et al. (2020). Treatment considerations for COVID-19: A critical review of the evidence (or lack thereof). Mayo Clinic Proceedings 95 (7): 1454-1466. doi: 10.1016/j.mayocp.2020.04.027
Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG et al. (2019). Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European Journal of Pharmacology 843: 251-259. doi: 10.1016/j. ejphar.2018.11.029
Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I et al. (2020). In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints 2020040315. doi: 10.20944/preprints202004.0315.v1
Watson CWM, Paolillo EW, Morgan EE, Umlauf A, Sundermann EE et al. (2020). Cannabis exposure is associated with a lower likelihood of neurocognitive impairment in people living with HIV. Journal of Acquired Immune Deficiency Syndromes 83 (1): 56-64. doi: 10.1097/ QAI.0000000000002211
Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS et al. (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and Experimental Immunology 136 (1): 95-103. doi: 10.1111/j.1365- 2249.2004.02415.x
Yagisawa M, Foster PJ, Hanaki H, Omura S (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics 74: 1. Access link:161/74-1_44-95
Yang H, Zhou J, Lehmann C (2016). GPR55–a putative “type 3” cannabinoid receptor in inflammation. Journal of Basic and Clinical Physiology and Pharmacology 27: 297-302. doi: 10.1515/jbcpp-2015-0080
Yang X, Yu Y, Xu J, Shu H, Liu H et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet Respiratory Medicine 8 (5): 475-481. doi: 10.1016/S2213- 2600(20)30079-5
Zgair A, Lee JB, Wong JC, Taha DA, Aram J et al. (2017). Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Scientific Reports 7 (1): 1-12. doi: 10.1038/s41598-017-15026-z
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020a). Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine 46 (4): 586-590. doi: 10.1007/s00134-020-05985-9
Zhang L, Lin D, Sun X, Curth U, Drosten C et al. (2020b). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368 (6489): 409-412. doi: 10.1126/science.abb3405
Zou S, Kumar U (2018). Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences 19 (3): 833. doi: 10.3390/ijms19030833
Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JE et al. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology 8: 259. doi: 10.3389/ fphar.2017.00259